Brief: Allurion Shifts Strategy Toward Low-Dose GLP-1 Combos, Muscle Health and US Entry
05/08/2025 14:17
Aug 5 (Reuters) - Allurion Technologies Inc ALUR.N: ALLURION ANNOUNCES NEW STRATEGIC DIRECTION WITH INCREASING FOCUS ON LOW-DOSE GLP-1 COMBINATION THERAPY, MUSCLE MASS MAINTENANCE, AND US MARKET ENTRY ALLURION TECHNOLOGIES INC - EXPECTS Q2 2025 REVENUE OF $3 MILLION, LOSS OF $7 MILLION Source text: ID:nBw9FqVV1a Further company coverage: ALUR.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allurion Technologies
See all newsBrief: Allurion Technologies Inc - Sees Growing Demand From Patients Discontinuing Glp-1 Therapy
Brief: Allurion Intends To Appeal NYSE Notice Of Delisting, Execute Plan To Regain Compliance, And Expects To Continue Trading On NYSE
Brief: NYSE To Commence Delisting Proceedings Against Allurion Technologies, Inc.
Allurion rises on plan to offer discounted weight-loss drug Mounjaro in Argentina
Allurion rises after strong weight-loss data from combination therapy